Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methoxyamine hydrochloride (Primary) ; Temozolomide
  • Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Lung cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 17 Jun 2020 Results published in the Investigational New Drugs.
    • 28 Feb 2019 According to a Tracon Pharmaceuticals media release, presentation of expanded cohort data by the National Cancer Institute from this trial in patients with colorectal, lung and ovarian cancer at the AACR annual meeting in Philadelphia is expected in April 2019.
    • 26 Jul 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top